{"id":55673,"date":"2025-11-06T13:38:15","date_gmt":"2025-11-06T17:38:15","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/trump-administration-secures-major-drug-price-cuts-from-eli-lilly-novo-nordisk-amidst-economic-headwinds\/55673\/"},"modified":"2025-11-06T13:38:15","modified_gmt":"2025-11-06T17:38:15","slug":"trump-administration-secures-major-drug-price-cuts-from-eli-lilly-novo-nordisk-amidst-economic-headwinds","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/trump-administration-secures-major-drug-price-cuts-from-eli-lilly-novo-nordisk-amidst-economic-headwinds\/55673\/","title":{"rendered":"Trump Administration Secures Major Drug Price Cuts from Eli Lilly, Novo Nordisk Amidst Economic Headwinds"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Eli Lilly<\/strong> (<a href=\"\/stock\/LLY\">LLY<\/a>) and <strong>Novo Nordisk<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>) have struck deals with the <strong><a href=\"https:\/\/thestockmarketwatch.com\/live\/trump-stock-market\" data-internallinksmanager029f6b8e52c=\"8\" title=\"Trump\">Trump<\/a> administration<\/strong> to significantly reduce prices for their popular obesity and diabetes drugs, including <strong>Zepbound<\/strong>, <strong>Wegovy<\/strong>, and <strong>Ozempic<\/strong>.<\/li>\n<li>Under the agreement, the lowest dose of Eli Lilly&#39;s <strong>Zepbound<\/strong> will be available to cash payers for <strong>$299 per month<\/strong>, with additional doses priced at <strong>$449<\/strong>. Similar pricing will apply to its experimental <strong>Orforglipron<\/strong> pill if approved.<\/li>\n<li><strong>Novo Nordisk<\/strong> will lower prices across all injectable <strong>Wegovy<\/strong> and <strong>Ozempic<\/strong> medicines, with the lowest dose of the anticipated <strong>Wegovy pill<\/strong> set at <strong>$149<\/strong> under the deal.<\/li>\n<li>These drug price reductions are part of a broader initiative by the <a href=\"https:\/\/thestockmarketwatch.com\/live\/trump-stock-market\" data-internallinksmanager029f6b8e52c=\"8\" title=\"Trump\">Trump<\/a> administration to make nearly all primary care drugs available at <strong>US net prices<\/strong> and, in many cases, <strong>Most Favored Nation prices<\/strong> through &quot;Trump Rx,&quot; slated for an early 2026 launch.<\/li>\n<li>The economic landscape remains challenging, with <strong>U.S. layoffs<\/strong> hitting a <strong>22-year high<\/strong> in October, as over <strong>153,000 jobs<\/strong> were cut\u2014the most since 2003\u2014marking a brutal start to the fourth quarter.<\/li>\n<\/ul>\n<p>The Trump administration has announced two significant deals with pharmaceutical giants <strong>Eli Lilly<\/strong> (<a href=\"\/stock\/LLY\">LLY<\/a>) and <strong>Novo Nordisk<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>), aimed at dramatically lowering the cost of key obesity and diabetes medications. These agreements are expected to bring substantial price reductions for consumers, particularly for cash payers.<\/p>\n<p>Under the terms of the deal, <strong>Eli Lilly<\/strong> (<a href=\"\/stock\/LLY\">LLY<\/a>) will make the lowest dose of its weight-loss drug <strong>Zepbound<\/strong> available to cash payers for <strong>$299 per month<\/strong>. Higher doses of the medication will be priced at <strong>$449 per month<\/strong>. These lower prices will also extend to Eli Lilly&#39;s experimental <strong>Orforglipron<\/strong> pill, should it receive regulatory approval. Furthermore, Eli Lilly will add its diabetes medicines <strong>Emgality<\/strong>, <strong>Trulicity<\/strong>, and <strong>Mounjaro<\/strong> to the program.<\/p>\n<p>Similarly, <strong>Novo Nordisk<\/strong> (<a href=\"\/stock\/NVO\">NVO<\/a>) has agreed to reduce prices across all its injectable <strong>Wegovy<\/strong> and <strong>Ozempic<\/strong> medicines. The lowest dose of the anticipated <strong>Wegovy pill<\/strong>, if approved, will be available for <strong>$149<\/strong> under this new arrangement. Novo Nordisk also committed to additional investment in U.S. manufacturing, including producing the <strong>Wegovy pill<\/strong> in the U.S. if it gains approval.<\/p>\n<p>Senior Trump administration officials stated that these agreements are part of a broader strategy to ensure Americans pay the lowest global prices for drugs. Nearly all primary care drugs are expected to be available at <strong>US net prices<\/strong> and, in many cases, <strong>Most Favored Nation prices<\/strong> when the &quot;Trump Rx&quot; platform launches in early 2026. Both pharmaceutical companies will also receive a <strong>3-year U.S. tariff reprieve<\/strong> as part of the deal.<\/p>\n<p>These developments in drug pricing come amidst a challenging economic backdrop. The U.S. economy saw a significant increase in layoffs in October, with over <strong>153,000 jobs cut<\/strong>, marking a <strong>22-year high<\/strong> and the most since 2003. This indicates a brutal start to the fourth quarter for the job market.<\/p>\n<p>Federal Reserve official Hammack offered a cautious outlook on monetary policy, stating it&#39;s &quot;not obvious&quot; the U.S. central bank should cut interest rates again given persistent inflation. Hammack expects inflation to overshoot the <strong>2% target by 1 percentage point<\/strong> this year and remain elevated in 2026, taking two to three years to return to target. Despite this, Hammack does not foresee a high probability of a labor market downturn, though acknowledging the job market may be more fragile than data suggests. Meanwhile, U.S. 30-year fixed-rate mortgages averaged <strong>6.22%<\/strong> in the November 6 week, up from <strong>6.17%<\/strong> the prior week.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Eli Lilly (LLY) and Novo Nordisk (NVO) have struck deals with the Trump administration to significantly reduce prices [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[7997,337,8762,3710,9442,3744,10085,4223,10832,4810,6065,6334,6422,6761],"class_list":["post-55673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-wegovy","tag-lly","tag-drug-prices","tag-federal-reserve","tag-orforglipron","tag-nvo","tag-ozempic","tag-inflation","tag-zepbound","tag-trump-administration","tag-layoffs","tag-novo-nordisk","tag-job-market","tag-eli-lilly"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/55673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=55673"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/55673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=55673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=55673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=55673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}